A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: An attractive candidate for melanoma vaccination

Cancer Immunology, Immunotherapy

Volumn 60, Issue 3, 2011, Pages 327-337

  Rogel, Anne ^a   Vignard, Virginie ^a,b   Bobinet, Mathilde ^a   Labarriere, Nathalie ^a   Lang, François ^a,c  

^a Team 12   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

CD4+ T cells; Melanoma; T cell epitope; Vaccination

Indexed keywords

EPITOPE; HLA A ANTIGEN; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DR ANTIGEN; MELAN A; MELANOMA VACCINE; MELOE 1[26-46]; MELOE 1[32-46]; MELOE 1[36-44]; PEPTIDE VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; MELOE 1 ANTIGEN, HUMAN; MELOE-1 ANTIGEN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOREACTIVITY; IMMUNOSTIMULATION; IN VITRO STUDY; MELANOMA; MOLECULAR CLONING; PEPTIDE ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; STANDARD;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-A ANTIGENS; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MELANOMA; NEOPLASM PROTEINS; REFERENCE STANDARDS;

EID: 79953816091     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0938-6     Document Type: Article

References (29)

1. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-915 (Pubitemid 39273730)
2. Melief CJ, van der Burg SH (2008) Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8:351-360 (Pubitemid 351589701)
3. Fayolle C, Deriaud E, Leclerc C (1991) In vivo induction of cytotoxic t cell response by a free synthetic peptide requires CD4+ T cell help. J Immunol 147:4069-4073
4. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH (2007) CD8+ CTL priming by exact peptide epitopes in incomplete freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 179:5033-5040
5. Gritzapis AD, Voutsas IF, Lekka E, Papamichail M, Baxevanis CN (2010) Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific fasL+ CD4+ T cells: first evidence for intratumor apoptotic regulatory T cells. Cancer Res 70:2686-2696
6. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361:1838-1847
7. Godet Y, Moreau-Aubry A, Guilloux Y, Vignard V, Khammari A, Dreno B, Jotereau F, Labarriere N (2008) Meloe-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med 205:2673-2682
8. Godet Y, Moreau-Aubry A, Mompelat D, Vignard V, Khammari A, Dreno B, Lang F, Jotereau F, Labarriere N (2010) An additional ORF on meloe cDNA encodes a new melanoma antigen, MELOE-2, recognized by melanoma-specific T cells in the HLA-A2 context. Cancer Immunol Immunother 59:431-439
9. Godet Y, Desfrancois J, Vignard V, Schadendorf D, Khammari A, Dreno B, Jotereau F, Labarriere N (2010) Frequent occurrence of high affinity t cells against meloe-1 makes this antigen an attractive target for melanoma immunotherapy. Eur J Immunol 40:1786-1794
10. Gervois N, Labarriere N, Le Guiner S, Pandolfino MC, Fonteneau JF, Guilloux Y, Diez E, Dreno B, Jotereau F (2000) High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells. Clin Cancer Res 6:1459-1467 (Pubitemid 30226235)
11. Davodeau F, Difilippantonio M, Roldan E, Malissen M, Casanova JL, Couedel C, Morcet JF, Merkenschlager M, Nussenzweig A, Bonneville M, Malissen B (2001) The tight interallelic positional coincidence that distinguishes t-cell receptor jalpha usage does not result from homologous chromosomal pairing during valphajalpha rearrangement. EMBO J 20:4717-4729 (Pubitemid 32848625)
12. Arden B, Clark SP, Kabelitz D, Mak TW (1995) Human t-cell receptor variable gene segment families. Immunogenetics 42:455-500 (Pubitemid 26025063)
13. Espevik T, Nissen-Meyer J (1986) A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95:99-105 (Pubitemid 17196641)
14. Faure F, Mantegazza A, Sadaka C, Sedlik C, Jotereau F, Amigorena S (2009) Long-lasting cross-presentation of tumor antigen in human dc. Eur J Immunol 39:380-390
15. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F, Napolitani G (2007) Surface phenotype and antigenic specificity of human interleukin 17-producing t helper memory cells. Nat Immunol 8:639-646 (Pubitemid 46785128)
16. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698-2703 (Pubitemid 351860862)
17. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, Matzinger P (2007) CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109:5346-5354 (Pubitemid 46890556)
18. Godefroy E, Scotto L, Souleimanian NE, Ritter G, Old LJ, Jotereau F, Valmori D, Ayyoub M (2006) Identification of two melan-a CD4+ T cell epitopes presented by frequently expressed MHC class II alleles. Clin Immunol 121:54-62 (Pubitemid 44389962)
19. Jager E, Jager D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A (2000) Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 191:625-630
20. Schultz ES, Lethe B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, Heirman C, Thielemans K, Boon T, van der Bruggen P (2000) A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic t lymphocytes. Cancer Res 60:6272-6275
21. Wang XF, Kerzerho J, Adotevi O, Nuyttens H, Badoual C, Munier G, Oudard S, Tu S, Tartour E, Maillere B (2008) Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients. J Immunol 181:431-439
22. Kobayashi H, Song Y, Hoon DS, Appella E, Celis E (2001) Tumor-reactive t helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res 61:4773-4778 (Pubitemid 32691890)
23. Kobayashi H, Lu J, Celis E (2001) Identification of helper t-cell epitopes that encompass or lie proximal to cytotoxic t-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res 61:7577-7584 (Pubitemid 32995051)
24. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL (1993) Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178:27-47 (Pubitemid 23173241)
25. Kennedy R, Celis E (2008) Multiple roles for CD4+ t cells in anti-tumor immune responses. Immunol Rev 222:129-144 (Pubitemid 351430378)
26. Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P (2006) Melan-a/mart-1-specific cd4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific t cells by MHC class II tetramers. J Immunol 177:6769-6779 (Pubitemid 44715041)
27. Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP (1999) Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic t cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 189:871-876 (Pubitemid 29189692)
28. Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P (1999) Identification of mage-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 189:767-778
29. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) Syfpeithi: database for MHC ligands and peptide motifs. Immunogenetics 50:213-219 (Pubitemid 30099526)